BOXED O
WARNING O
: O
WARNING O
: O
RISK O
OF O
THYROID O
C-CELL O
TUMORS O
WARNING O
: O
RISK O
OF O
THYROID O
C-CELL O
TUMORS O
* O
Liraglutide O
causes O
dose-dependent O
and O
treatment-duration-dependent O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
at O
clinically O
relevant O
exposures O
in O
both O
genders O
of O
rats O
and O
mice O
. O

It O
is O
unknown O
whether O
VICTOZA O
causes O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
, O
including O
medullary B-NonOSE_AE
thyroid I-NonOSE_AE
carcinoma I-NonOSE_AE
( I-NonOSE_AE
MTC I-NonOSE_AE
) O
, O
in O
humans O
, O
as O
the O
human O
relevance O
of O
liraglutide-induced O
rodent O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
has O
not O
been O
determined O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

* O
VICTOZA O
is O
contraindicated O
in O
patients O
with O
a O
personal O
or O
family O
history O
of O
MTC B-Not_AE_Candidate
and O
in O
patients O
with O
Multiple B-Not_AE_Candidate
Endocrine I-Not_AE_Candidate
Neoplasia I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
type I-Not_AE_Candidate
2 I-Not_AE_Candidate
( I-Not_AE_Candidate
MEN I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
. O

Counsel O
patients O
regarding O
the O
potential O
risk O
for O
MTC B-NonOSE_AE
with O
the O
use O
of O
VICTOZA O
and O
inform O
them O
of O
symptoms O
of O
thyroid B-NonOSE_AE
tumors I-NonOSE_AE
( O
e.g O
. O

a O
mass B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
, O
dysphagia B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
persistent B-NonOSE_AE
hoarseness I-NonOSE_AE
) O
. O

Routine O
monitoring O
of O
serum O
calcitonin O
or O
using O
thyroid O
ultrasound O
is O
of O
uncertain O
value O
for O
early O
detection O
of O
MTC B-NonOSE_AE
in O
patients O
treated O
with O
VICTOZA O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
RISK O
OF O
THYROID O
C-CELL O
TUMORS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Liraglutide O
causes O
thyroid O
C-cell O
tumors O
at O
clinically O
relevant O
exposures O
in O
both O
genders O
of O
rats O
and O
mice O
. O

It O
is O
unknown O
whether O
VICTOZA O
causes O
thyroid O
C-cell O
tumors O
, O
including O
medullary O
thyroid O
carcinoma O
( O
MTC O
) O
, O
in O
humans O
, O
as O
the O
human O
relevance O
of O
liraglutide-induced O
rodent O
thyroid O
C-cell O
tumors O
has O
not O
been O
determined O
( O
5.1 O
, O
13.1 O
) O
. O

* O
VICTOZA O
is O
contraindicated O
in O
patients O
with O
a O
personal O
or O
family O
history O
of O
MTC O
or O
in O
patients O
with O
Multiple O
Endocrine O
Neoplasia O
syndrome O
type O
2 O
( O
MEN O
2 O
) O
. O

Counsel O
patients O
regarding O
the O
potential O
risk O
of O
MTC O
and O
the O
symptoms O
of O
thyroid O
tumors O
( O
4 O
, O
5.1 O
) O
. O

